Skip to main content
News & Press Releases

Imagin Medical Starts Trading On the CSE

By 23 February 2016August 11th, 2022No Comments

Vancouver, B.C., February 23, 2016 – Imagin Medical Inc. (formerly Expedition Mining Inc.) announces that further to its news release dated February 10, 2016, the Canadian Securities Exchange (“CSE”) has approved the Company’s Listing Statement dated February 18, 2016, and it is now posted on the CSE and SEDAR websites. 

The Company’s common shares will resume trading on the CSE on Wednesday, February 24, 2016 under the symbol “IME”. 

The Listing Statement provides full disclosure of Imagin Medical’s new business, its directors and officers, and share capital structure. Shareholders and potential investors are encouraged to review that document in addition to Imagin Medical’s earlier news releases. 

Imagin Medical also announces that it has closed Tranche 2 of its private placement through the issuance of 330,000 units at $0.15, each unit comprised of one share and one warrant exercisable for a period of two years at $0.25 in the first 12 months and at $0.35 thereafter. In connection with Tranche 2, the Company issued finder’s warrants entitling the warrant holder to acquire 25,600 shares at $0.15 per share for 24 months. The funds raised in Tranche 2 will be used for continued market and product development and general working capital. 

“We are pleased to have our Company’s shares listed on the CSE, which will give our shareholders a reflection of Imagin Medical’s value as we move our technology through development to commercialization,” said Jim Hutchens, Imagin Medical’s new President. “We are excited about the future and the prospects it offers to both our shareholders and the medical industry.” 

About Imagin Medical The Next Generation Ultrasensitive Imaging Solutions for Early Detection and Treatment of Cancer 

Imagin Medical Inc. is a medical imaging company positioned to radically improve the way physicians detect cancer through the use of endoscopes. Imagin’s initial target market is bladder cancer, the ninth most common cancer globally, but the most expensive cancer to treat in the U.S. Dr. Stavros Demos, from the renowned Lawrence Livermore National Laboratory, is the inventor of the i/Blue (combination optical/laser) System for the accurate visual detection of cancer. Dr. Demos worked in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer, to determine feasibility. 



Jim Hutchens, 

CEO, President 

For further information, contact: 

Bill Galine 

Telephone: (775) 737-3292 

Email: [email protected] 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. 

This press release is not an offer or a solicitation of an offer of securities for sale in the United States of America. The common shares of Imagin Medical Inc. have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.